Anti-obesity drugs

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 536-543

  Rankin, Wayne ^a,b,c   Wittert, Gary ^a,c  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b Chemical Pathology   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

generalizability; individualization; liraglutide; lorcaserin; obesity; side effects

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMINOPEPTIDASE INHIBITOR; ANTIOBESITY AGENT; LIRAGLUTIDE; LORCASERIN; METHIONINE AMINOPEPTIDASE 2 INHIBITOR; METHIONYL AMINOPEPTIDASE 2; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG EFFICACY; EUROPEAN; HUMAN; HYPERTENSION; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; OBESITY;

EID: 84957426814     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000232     Document Type: Review

References (39)

1. Martin-Rodriguez E, Guillen-Grima F, Martí A, Brugos-Larumbe A. Comorbidity associated with obesity in a large population: The APNA study. Obes Res Clin Pract 2015. [Epub ahead of print] doi: 10.1016/j.orcp.2015.04.003.
2. Porter Starr KN, Bales CW. Excessive body weight in older adults. Clin Geriatr Med 2015; 31:311-326.
3. Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr 2015. [Epub ahead of print]. doi:10.1017/S0007114515002093.
4. Kakkar AK, Dahiya N. Drug treatment of obesity: current status and future prospects. Eur J Intern Med 2015; 26:89-94.
5. Kumar RB, Aronne LJ. Efficacycomparison ofmedicationsapproved forchronic weight management. Obesity (Silver Spring) 2015; 23 (Suppl 1):S4-S7.
6. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100:342-362.
7. Halpern B, Halpern A. Safety assessment of FDA-approved (Orlistat and Lorcaserin) antiobesity medications. Expert Opin Drug Saf 2015; 14:305-315.
8. Burke LK, Heisler LK. 5-hydroxytryptamine medications for the treatment of obesity. J Neuroendocrinol 2015; 27:389-398.
9. Schellekens H, De Francesco PN, Kandil D, et al. Ghrelin's orexigenic effect is modulated via a serotonin 2c receptor interaction. ACS Chem Neurosci 2015; 6:1186-1197.
10. Voigt JP, Fink H. Serotonin controlling feeding and satiety. Behav Brain Res 2015; 277:14-31.
11. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of Lorcaserin for weight management. N Engl J Med 2010; 363:245-256.
12. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-3077.
13. Aronne L, Shanahan W, Fain R, et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Postgrad Med 2014; 126:7-18.
14. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20:1426-1436.
15. Smith SR, O'Neil PM, Astrup A, et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014; 22:2137-2146.
16. DiNicolantonio JJ, Chatterjee S, O'Keefe JH, Meier P. Lorcaserin for the treatment of obesity? A closer look at its side effects. Open Heart 2014; 1:e000173.
17. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011. (10):CD006423 doi: 10.1002/14651858.CD006423.pub2.
18. Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One 2015; 10:e0126769. doi: 10.1371/journal.pone.0126769.
19. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, nondiabetic adults. Int J Obes (Lond) 2014; 38:784-793.
20. Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab 2012; 14:531-538.
21. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374:1606-1616.
22. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.
23. Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, nondiabetic adults. Int J Obes (Lond) 2014; 38:689-697.
24. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0mg of Liraglutide in weight management. N Engl J Med 2015; 373:11-22.
25. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37:1443-1451.
26. Sauer N, Reining F, Schulze Zur Wiesch C, et al. Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice. Horm Metab Res 2015; 47:560-564.
27. Singh J, Kumar R. Phentermine-topiramate: first combination drug for obesity. Int J Appl Basic Med Res 2015; 5:157-158.
28. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341-1352.
29. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297-308.
30. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330-342.
31. Neoh SL, Sumithran P, Haywood CJ, et al. Combination phentermine and topiramate for weight maintenance: the first Australian experience. Med J Aust 2014; 201:224-226.
32. Alfaris N, Minnick AM, Hopkins CM, et al. Combination phentermine and topiramate extended release in the management of obesity. Expert Opin Pharmacother 2015; 16:1263-1274.
33. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21:935-943.
34. Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2014; 13:831-841.
35. Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8:1419-1427.
36. Joharapurkar AA, Dhanesha NA, Jain MR. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity. Diabetes Metab Syndr Obes 2014; 7:73-84.
37. Kim DD, Krishnarajah J, Lillioja S, et al. Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab 2015; 17:566-572.
38. Gault VA, Bhat VK, Irwin N, Flatt PR. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucosedependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem 2013; 288:35581-35591.
39. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015; 21:27-36.